Literature DB >> 20499293

Clinicopathologic prognostic factors of pure myxoid liposarcoma of the extremities and trunk wall.

Yoshihiro Nishida1, Satoshi Tsukushi, Hiroatsu Nakashima, Naoki Ishiguro.   

Abstract

BACKGROUND: Myxoid liposarcoma is generally considered a low grade tumor but the presence of areas of round cells exceeding 5% is reportedly associated with a worse prognosis. Whether "pure" tumors without round cells are low grade has not been confirmed. While radiotherapy has been used for patients' myxoid liposarcoma it is unclear whether it reduces local recurrences. QUESTIONS/PURPOSES: We therefore determined the survival, roles of radiotherapy for local control, and prognostic factors of pure myxoid liposarcoma of the extremities and trunk wall.
METHODS: We retrospectively reviewed 53 patients histologically diagnosed with pure myxoid liposarcoma arising in extremities and the trunk wall. Nine patients of the 53 received radiotherapy for primary tumors. Clinical features and prognosis was determined, and various factors were analyzed as to their usefulness as prognostic factors (age, gender, location, size, depth, surgical margin, and adjuvant radiotherapy). The minimum followup was 12 months (mean, 60 months; range, 12-226 months).
RESULTS: Seven (13%) and 6 (11%) patients developed a local recurrence and distant metastasis, respectively. The 5- and 10-year disease-specific and disease-free survival rates were 90% and 83% and 77% and 77%, respectively. Radiotherapy had no impact on either overall or disease free survival. Age (older than 60 years) independently predicted worse overall and disease-free survival.
CONCLUSIONS: In pure myxoid liposarcoma located in the extremities and trunk wall, relatively few patients developed distant metastasis suggesting the tumor is generally low grade. Local control could be achieved with wide surgical margins without radiotherapy. Age was associated with lower survival but size and depth were not. Myxoid liposarcoma in older patients requires special consideration for treatment and followup.

Entities:  

Mesh:

Year:  2010        PMID: 20499293      PMCID: PMC2947684          DOI: 10.1007/s11999-010-1396-3

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  19 in total

1.  Postoperative nomogram for 12-year sarcoma-specific death.

Authors:  Michael W Kattan; Denis H Y Leung; Murray F Brennan
Journal:  J Clin Oncol       Date:  2002-02-01       Impact factor: 44.544

2.  Influence of biologic factors and anatomic site in completely resected liposarcoma.

Authors:  D C Linehan; J J Lewis; D Leung; M F Brennan
Journal:  J Clin Oncol       Date:  2000-04       Impact factor: 44.544

3.  Pleomorphic liposarcoma: clinicopathologic, immunohistochemical, and follow-up analysis of 63 cases: a study from the French Federation of Cancer Centers Sarcoma Group.

Authors:  Sandra Gebhard; Jean-Michel Coindre; Jean-Jacques Michels; Philippe Terrier; Gérard Bertrand; Martine Trassard; Sophia Taylor; Marie-Christine Château; Bernard Marquès; Véronique Picot; Louis Guillou
Journal:  Am J Surg Pathol       Date:  2002-05       Impact factor: 6.394

4.  The rationale for planned reoperation after unplanned total excision of soft-tissue sarcomas.

Authors:  A E Giuliano; F R Eilber
Journal:  J Clin Oncol       Date:  1985-10       Impact factor: 44.544

5.  Metastatic patterns of extremity myxoid liposarcoma and their outcome.

Authors:  Susanne H Estourgie; Gunnlaugur P Nielsen; Mark J Ott
Journal:  J Surg Oncol       Date:  2002-06       Impact factor: 3.454

Review 6.  Biology of aging as related to cancer.

Authors:  H J Cohen
Journal:  Cancer       Date:  1994-10-01       Impact factor: 6.860

7.  Dedifferentiated liposarcoma. Clinicopathologic analysis of 32 cases suggesting a better prognostic subgroup among pleomorphic sarcomas.

Authors:  D McCormick; T Mentzel; A Beham; C D Fletcher
Journal:  Am J Surg Pathol       Date:  1994-12       Impact factor: 6.394

8.  Pleomorphic liposarcoma: clinicopathologic analysis of 57 cases.

Authors:  Jason L Hornick; Marcus W Bosenberg; Thomas Mentzel; Máirín E McMenamin; Andre M Oliveira; Christopher D M Fletcher
Journal:  Am J Surg Pathol       Date:  2004-10       Impact factor: 6.394

9.  Liposarcoma: outcome based on the Scandinavian Sarcoma Group register.

Authors:  Katarina Engström; Peter Bergh; Pelle Gustafson; Ragnar Hultborn; Helena Johansson; Rickard Löfvenberg; Olga Zaikova; Clement Trovik; Ola Wahlström; Henrik C F Bauer
Journal:  Cancer       Date:  2008-10-01       Impact factor: 6.860

10.  Sarcomas and other malignancies of soft tissue, retroperitoneum, peritoneum, pleura, heart, mediastinum, and spleen.

Authors:  T M Mack
Journal:  Cancer       Date:  1995-01-01       Impact factor: 6.860

View more
  21 in total

1.  Myxoid liposarcoma with cartilaginous differentiation showing DDIT3 rearrangement.

Authors:  Kayo Suzuki; Taketoshi Yasuda; Kenta Watanabe; Takeshi Hori; Masahiko Kanamori; Tomoatsu Kimura
Journal:  Oncol Lett       Date:  2017-09-25       Impact factor: 2.967

2.  Establishment and characterization of a new human myxoid liposarcoma cell line (DL-221) with the FUS-DDIT3 translocation.

Authors:  Marieke A de Graaff; Jamie S E Yu; Hannah C Beird; Davis R Ingram; Theresa Nguyen; Jeffrey Juehui Liu; Svetlana Bolshakov; Károly Szuhai; Pierre Åman; Keila E Torres; Dina Lev; Torsten O Nielsen; Judith V M G Bovée; Alexander J Lazar; Neeta Somaiah
Journal:  Lab Invest       Date:  2016-06-06       Impact factor: 5.662

3.  Primary High-Grade Myxoid Liposarcoma of the Extremities: Prognostic Factors and Metastatic Pattern.

Authors:  Gianmarco Tuzzato; Roberta Laranga; Federico Ostetto; Elisa Bubbico; Giulio Vara; Giuseppe Bianchi
Journal:  Cancers (Basel)       Date:  2022-05-27       Impact factor: 6.575

Review 4.  Myxoid liposarcoma originating in the retroperitoneum with metastasis to the calcaneus: a rare case report and review of literature.

Authors:  Kazuhiko Hashimoto; Shunji Nishimura; Seiichiro Mitani; Tomohiko Ito; Masao Akagi
Journal:  Skeletal Radiol       Date:  2022-03-06       Impact factor: 2.128

5.  Molecular signatures of tumor progression in myxoid liposarcoma identified by N-glycan mass spectrometry imaging.

Authors:  Liam A McDonnell; Judith V M G Bovée; Bram Heijs; Stephanie Holst-Bernal; Marieke A de Graaff; Inge H Briaire-de Bruijn; Mar Rodriguez-Girondo; Michiel A J van de Sande; Manfred Wuhrer
Journal:  Lab Invest       Date:  2020-04-27       Impact factor: 5.662

6.  Surgery quality and tumor status impact on survival and local control of resectable liposarcomas of extremities or the trunk wall.

Authors:  Piotr Rutkowski; Sławomir Trepka; Konrad Ptaszynski; Milena Kołodziejczyk
Journal:  Clin Orthop Relat Res       Date:  2013-03       Impact factor: 4.176

Review 7.  Management of myxoid liposarcoma of the extremity.

Authors:  Yehia Tfayli; Ahmad Baydoun; Ahmad Salaheddine Naja; Said Saghieh
Journal:  Oncol Lett       Date:  2021-06-09       Impact factor: 2.967

8.  Myxoid liposarcoma with negative features on bone scan and [18F]-2-fluoro-2-deoxy-D-glucose-positron emission tomography.

Authors:  Akio Sakamoto; Yoshiaki Fukutoku; Yoshihiro Matsumoto; Katsumi Harimaya; Yoshinao Oda; Yukihide Iwamoto
Journal:  World J Surg Oncol       Date:  2012-10-09       Impact factor: 2.754

9.  Cytogenetics and molecular genetics of myxoid soft-tissue sarcomas.

Authors:  Jun Nishio; Hiroshi Iwasaki; Kazuki Nabeshima; Masatoshi Naito
Journal:  Genet Res Int       Date:  2011-07-28

10.  Metastatic pattern, local relapse, and survival of patients with myxoid liposarcoma: a retrospective study of 45 patients.

Authors:  Hanna M Fuglø; Katja Maretty-Nielsen; Dorrit Hovgaard; Johnny Ø Keller; Akmal A Safwat; Michael M Petersen
Journal:  Sarcoma       Date:  2013-06-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.